Alpha 2.0
Login Register
» Authors » Ziyi Lim

Ziyi Lim

Explore the profile of Ziyi Lim including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 441
Followers 0
Related Specialties
Hematology
Oncology
Infectious Diseases
Top 10 Co-Authors
Ghulam J Mufti
Antonio Pagliuca
Stephen Devereux
Aloysius Y L Ho
Karthik Ramasamy
Janet Hayden
Linda D Barber
Katie Matthews
Behdad Afzali
Giovanna Lombardi
Published In
Br J Haematol
Leuk Lymphoma
Haematologica
Blood
Pediatr Blood Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome
Potter V, Krishnamurthy P, Barber L, Lim Z, Kenyon M, Ireland R, et al.
Biol Blood Marrow Transplant . 2013 Nov; 20(1):111-7. PMID: 24216184
Allogeneic hematopoietic stem cell transplantation (HSCT) with reduced-intensity conditioning (RIC) offers a potential cure for patients with myelodysplastic syndrome (MDS) who are ineligible for standard-intensity regimens. Previously published data from...
2.
Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients
Moses S, Lim Z, Zuckerman M
Expert Rev Anti Infect Ther . 2011 Oct; 9(10):891-9. PMID: 21973301
Hepatitis B virus (HBV) is a partially double stranded DNA virus that can integrate into host cell chromosomes as covalently closed circular DNA forms. HBV reactivation following hematopoietic stem cell...
3.
Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience
Ramasamy K, Mahmood S, Lim Z, Corderoy S, Devereux S, Mufti G, et al.
Clin Lymphoma Myeloma Leuk . 2011 May; 11(2):242-5. PMID: 21575930
Background: Reduced-intensity conditioning allogeneic transplantation for myeloma is associated with lower non-relapse mortality and higher relapse rates in comparison with myeloablative conditioning transplants. Patients And Methods: We have retrospectively audited...
4.
Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia
Marsh J, Gupta V, Lim Z, Ho A, Ireland R, Hayden J, et al.
Blood . 2011 Apr; 118(8):2351-7. PMID: 21518925
We evaluated a novel alemtuzumab-based conditioning regimen in HSCT for acquired severe aplastic anemia (SAA). In a multicenter retrospective study, 50 patients received transplants from matched sibling donors (MSD; n...
5.
Outcome of Chinese children with unrelated donor hematopoietic stem cell transplantation
Chen J, Lim Z, Luo C, Jiang H, Luo C, Tang J, et al.
Pediatr Blood Cancer . 2010 Oct; 55(7):1386-92. PMID: 20981693
Background: To evaluate the prognostic factors and outcomes in Chinese children undergoing unrelated donor hematopoietic stem cell transplantation (UDT). Methods: Retrospective analysis of clinical data from 53 consecutive children who...
6.
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value
Smith A, Mohamedali A, Kulasekararaj A, Lim Z, Gaken J, Lea N, et al.
Blood . 2010 Aug; 116(19):3923-32. PMID: 20693430
Mutations in the TET2 gene are frequent in myeloid disease, although their biologic and prognostic significance remains unclear. We analyzed 355 patients with myelodysplastic syndromes using "next-generation" sequencing for TET2...
7.
Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab
Matthews K, Lim Z, Pearce L, Pagliuca A, Madrigal J, Mufti G, et al.
Br J Haematol . 2010 Mar; 149(6):879-89. PMID: 20346011
Graft-versus-leukaemia (GvL) and graft-versus-host disease (GvHD) are both caused by alloreactive lymphocytes. We previously reported that GvHD correlated with higher numbers of effector CD4 T cells and Natural Killer cells...
8.
Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia
Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, et al.
J Clin Oncol . 2009 Dec; 28(3):405-11. PMID: 20008642
Purpose: This study was performed to examine the characteristics of transplant activity for patients with myelodysplastic syndromes (MDS) older than 50 years within the European Group for Blood and Marrow...
9.
Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab
Matthews K, Lim Z, Afzali B, Pearce L, Abdallah A, Kordasti S, et al.
Haematologica . 2009 Jun; 94(7):956-66. PMID: 19491336
Background: A variety of immune pathways can lead to graft-versus-host disease. A better understanding of the type of immune response causing graft-versus-host disease in defined clinical hematopoietic stem cell transplant...
10.
IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome
Kordasti S, Afzali B, Lim Z, Ingram W, Hayden J, Barber L, et al.
Br J Haematol . 2009 Feb; 145(1):64-72. PMID: 19210506
Immunological responses are increasingly recognised as being important in the initiation and progression of myelodysplastic syndrome (MDS). Indeed, autoimmune diseases commonly occur in association with MDS, particularly in subtypes with...